A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
Clinical data | |
---|---|
Other names | IBI362; LY3305677 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C207H317N45O65 |
Molar mass | 4476.063 g·mol−1 |
3D model (JSmol) | |
| |
|
Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).[1][2][3] The drug is developed by Eli Lilly and is currently in a Phase II study.[4]
Referencesedit
- ^ Jiang, Hongwei; Pang, Shuguang; Zhang, Yawei; Yu, Ting; Liu, Meng; Deng, Huan; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei; Yang, Wenying (24 June 2022). "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes". Nature Communications. 13 (1): 3613. doi:10.1038/s41467-022-31328-x. ISSN 2041-1723. PMC 9232612. PMID 35750681.
- ^ Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei (December 2022). "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial". eClinicalMedicine. 54: 101691. doi:10.1016/j.eclinm.2022.101691. PMC 9561728. PMID 36247927.
- ^ Ji, Linong; Jiang, Hongwei; An, Pei; Deng, Huan; Liu, Meng; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei (September 2021). "IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study". eClinicalMedicine. 39: 101088. doi:10.1016/j.eclinm.2021.101088. PMC 8374649. PMID 34430840.
- ^ "Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?". Retrieved 4 November 2023.
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.
Antropológia
Aplikované vedy
Bibliometria
Dejiny vedy
Encyklopédie
Filozofia vedy
Forenzné vedy
Humanitné vedy
Knižničná veda
Kryogenika
Kryptológia
Kulturológia
Literárna veda
Medzidisciplinárne oblasti
Metódy kvantitatívnej analýzy
Metavedy
Metodika
Text je dostupný za podmienok Creative
Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších
podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky
použitia.
www.astronomia.sk | www.biologia.sk | www.botanika.sk | www.dejiny.sk | www.economy.sk | www.elektrotechnika.sk | www.estetika.sk | www.farmakologia.sk | www.filozofia.sk | Fyzika | www.futurologia.sk | www.genetika.sk | www.chemia.sk | www.lingvistika.sk | www.politologia.sk | www.psychologia.sk | www.sexuologia.sk | www.sociologia.sk | www.veda.sk I www.zoologia.sk